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Ficolina b s t r a c t
Ficolin-2 has been reported to bind to DNA and heparin, but the mechanism involved has not been
thoroughly investigated. X-ray studies of the ﬁcolin-2 ﬁbrinogen-like domain in complex with
several new ligands now show that sulfate and phosphate groups are prone to bind to the S3 binding
site of the protein. Composed of Arg132, Asp133, Thr136 and Lys221, the S3 site was previously
shown to mainly bind N-acetyl groups. Furthermore, DNA and heparin compete for binding to
ﬁcolin-2. Mutagenesis studies reveal that Arg132, and to a lesser extent Asp133, are important for
this binding property. The versatility of the S3 site in binding N-acetyl, sulfate and phosphate groups
is discussed through comparisons with homologous ﬁbrinogen-like recognition proteins.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Initially discovered as a N-acetylglucosamine (GlcNAc) recogni-
tion protein with structural and functional similarities to collectins
[1], human ﬁcolin-2 has then been shown to bind to a wider
variety of non-self and self molecular patterns [2]. It plays a major
role in the ﬁrst line of defense, for example against pneumococcal
infections [3,4]. Ficolin-2 also acts as a scavenger molecule,
promoting non-inﬂammatory removal of dying host cells or
mitochondria [5–7].Three different ﬁcolins are found in humans, namely ﬁcolin-1, -
2 and -3 (also called M-, L- and H-ﬁcolin) and two in rodents,
ﬁcolin-A and -B, while homologous molecules were also discov-
ered in invertebrate species [8]. The recognition properties of ﬁco-
lins are mediated by their C-terminal trimeric ﬁbrinogen-like (FBG)
domains [9]. They assemble into higher oligomeric forms through
their N-terminal collagen-like region, which, except for mouse ﬁc-
olin-B, also binds mannan-binding lectin-associated serine prote-
ase-1 and -2 to trigger the lectin complement pathway [10].
Ficolins are characterized by their capacity to bind acetylated
ligands, including carbohydrates such as GlcNAc and acetylated
bovine serum albumin (AcBSA) [11–13]. It is now well established
that ﬁcolin-2 exhibits a wider binding versatility than the other
two human ﬁcolins [2], as exempliﬁed by its capacity to bind to
DNA [5], a ligand shared with mouse ﬁcolin-B [14], and heparin
[2]. Since DNA is present at the surface of apoptotic/necrotic cells,
its interaction with ﬁcolin-2 has been proposed to contribute to
enhanced uptake and clearance of dying cells, thereby participat-
ing to the maintenance of tissue homeostasis [5]. Heparin is known
to interact with several complement proteins and to regulate sev-
eral steps in the complement cascade [15]. Interestingly, it has
been proposed that properdin, a component of the alternative
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surface sulfated glycosaminoglycans chains [16], but it is not
known if it is also the case for ﬁcolin-2.
Structural analyses have provided some clues to this distinctive
feature by revealing the lack of a functional S1 acetyl binding site,
and the presence of three additional sub-sites, called S2, S3 and S4,
allowing interaction with small acetylated ligands in various orien-
tations (S2 and S3) and with elongated glycans (S3 and S4) [9]. The
binding speciﬁcity of ﬁcolin-2 for heparin and DNA has not yet
been investigated in detail.
A novel member of the family of FBG domain containing pro-
teins, called Fibrinogen C Domain Containing Protein 1 (FIBCD1)
with binding speciﬁcity for chitin, a polymer of b1-4 linked glucose
units, has been identiﬁed recently [17]. Resolution of the X-ray
crystal structure of its FBG domain in complex with N-acetylman-
nosamine conﬁrmed the presence of the canonical S1 acetyl bind-
ing site [18]. Interestingly, the FIBCD1 site corresponding to the
acetyl-binding site S3 of ﬁcolin-2 contained a sulfate ion and the
proximity of the acetyl and sulfate sites suggested that FIBCD1
might bind glycosaminoglycans such as chondroitin or dermatan
sulfate [18].
In the present study, structural analyses of complexes of the ﬁc-
olin-2 FBG domain with sulfated ligands allowed us to show simi-
lar interactions of distinct chemical groups with the acetyl binding
site S3 while site-directed mutagenesis identiﬁed the predominant
role of Arg132 in these interactions.
2. Materials and methods
2.1. Reagents
Heparin and heparin-biotin sodium salt (mw 15 kDa) from
porcine intestinal mucosa, glycerol phosphate disodium salt
hydrate, phosphocholine chloride calcium salt tetrahydrate (PCho),
D-glucosamine-6-sulfate (6SGlcN), bovine serum albumin (BSA, ref
A 7906), acetylated BSA (AcBSA) and gelatin were from
Sigma–Aldrich, IL, USA (Saint Quentin Fallavier, France). Calf
thymus DNA (2000 bp, corresponding to a molecular mass
1300000 Da assuming a mass of 650 Da per bp) was from Invit-
rogen (Cergy-Pontoise, France). Sucrose octasulfate sodium salt
(SOS) was purchased from US Biological (Salem, MA, USA).
2.2. Production and puriﬁcation of human ﬁcolin-2 variants
Recombinant human ﬁcolin-2 was produced in Chinese hamster
ovary cells and puriﬁed using a one-step afﬁnity chromatography
on N-acetylcysteine-Sepharose [13]. The concentration of ﬁcolin-
2 was estimated using an absorbance coefﬁcient at 280 nm (A1%,
1 cm) of 17.6 and the molarity estimated using a Mr value of
406300, assuming that the proteins mainly associates as a tetra-
mer of trimers.
The expression plasmids coding for the R132A, D133A, T136A
and K221A mutants of ﬁcolin-2 were generated using the Quick-
Change II XL Site-Directed Mutagenesis Kit (Agilent Technologies,
Massy, France) according to the manufacturer’s protocol. A
pcDNA3.1(+) vector coding for full-length ﬁcolin-2 was used as a
template [13]. Mutagenic oligonucleotides were purchased from
Eurogentec (Seraing, Belgium). The sequences of all constructs
were veriﬁed by dsDNA sequencing (GATC Biotech, Mulhouse,
France). The mutated proteins were produced by transient trans-
fection of CHO cells using Lipofectamine 2000 (Invitrogen), as
described by the manufacturer. Cells were cultured for 4 days in
DMEM:F12 medium (Invitrogen) containing 10% heat-inactivated
fetal calf serum and 50 lg/ml ascorbic acid (Sigma–Aldrich). The
ﬁcolin-2 mutants were puriﬁed from the cell culture supernatant
and their molar concentrations estimated as described for thewild-type (wt) protein [13]. Analysis of all variants by SDS–PAGE
and Coomassie blue staining or western blotting yielded typical
patterns, including a single band with an apparent Mr of
34000 Da under reducing conditions and two major bands, one
of Mr 34000 and the other of high molecular weight, under non-
reducing conditions (Fig. S1), as described previously for other
ﬁcolin-2 variants [13].
2.3. Solid-phase binding assays
A solid-phase binding assay was performed to measure binding
of the ﬁcolin-2 variants to immobilized heparin. Clear 96-well
microtiter plates (heparin binding plates, Becton–Dickinson, Le
Pont de Claix, France) were coated with 2.5 lg/well heparin or gel-
atin as a control in 100 ll of PBS overnight at room temperature
(RT). Wells were blocked with 0.2% gelatin in PBS for 2 h at
37 C, washed with PBS containing 0.05% Tween 20 (PBS-T) and
0.5 lg of ﬁcolin-2 diluted in PBS-T were added and incubated for
2.5 h at 37 C. After washing with PBS-T, ﬁcolin-2 binding was
detected by incubation for 1 h at 37 C with a rabbit polyclonal
antibody against ﬁcolin-2 (ST1689, Merck Millipore, Guyancourt,
France) diluted 1/1000 in PBS-T. After washing with PBS-T, HRP-
conjugated anti-rabbit IgG (Sigma–Aldrich) diluted 1/20000 in
PBS-T was added and incubated for 1 h at 37 C. After washing with
PBS-T, plates were developed with tetramethylbenzidine, the reac-
tion was sopped with 0.5 M H2SO4 and absorbance was read at
450 nm.
2.4. Surface plasmon resonance studies
Analyses were performed at 25 C using a Biacore 3000 instru-
ment (GE Healthcare). Streptavidin (approximately 4000 RU) was
immobilized on two ﬂow cells of a CM4 sensor chip (GE Health-
care) as described previously [19]. Biotinylated heparin was cap-
tured on the streptavidin surface in 10 mM HEPES, 145 mM NaCl,
0.005% surfactant P20, pH 7.4 (HBS-P) until a coupling level of
250–300 RU was obtained. AcBSA and BSA were diluted to 25 lg/
ml in 10 mM sodium formate, pH 3.0 and 10 mM sodium acetate,
pH 4.0, respectively, and immobilized (650–950 RU) on a CM5 sen-
sor chip in HBS-P using the amine coupling chemistry according to
the manufacturer instructions (GE Healthcare Life Sciences, Velizy-
Villacoublay, France). Ficolin-2 binding was measured in HBS-P at a
ﬂow rate of 20 ll/min. The heparin and AcBSA surfaces were
regenerated by pulse injections of 1 M NaCl and 1 M sodium ace-
tate (pH 7.2), respectively. The signal recorded on reference ﬂow
cells without captured heparin or with immobilized BSA were sub-
tracted from that obtained on biotinylated heparin or AcBSA,
respectively.
For competition assays, ﬁcolin-2 was incubated for 15 min at
room temperature in the presence of various concentrations of
competitor before injection. The signal recorded for injection of
the competitor alone was subtracted from the data.
2.5. Crystallization, data collection and structure determination
Crystallization of recombinant ﬁcolin-2 FBG domain, ligand
soaking and structure determination were performed as described
before [9]. Brieﬂy, crystals were grown using the hanging drop
method by mixing equal volumes (2 ll) of the protein solution
(5.7 mg/ml in 145 mM NaCl, 50 mM triethanolamine-HCl, pH 7.4)
and of a reservoir solution composed of 15% (w/v) polyethylene
glycol (PEG) 8000, 200 mM calcium acetate and 0.1 M HEPES, pH
7.0. Different ligand concentrations and soaking times were tried,
but the best results in terms of diffraction resolution were selected
here. They correspond to two soaking experiments, one using
150 mM SOS for 10 min and the other 300 mM 6SGlcN for 4 h.
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before ﬂash-cooling the crystal in liquid nitrogen. Diffraction data
were recorded at the European Synchrotron Radiation Facility
(ESRF) synchroton beamlines ID23-eh1 and ID23-eh2, respectively.
The position and orientation of the ﬁcolin-2 FBG trimer in the
P3221 space group were determined with the molecular replace-
ment software Phaser [20]. Alternative cycles of reﬁnement and
graphics edition were performed using Refmac5 [21] and Coot
[22], respectively. Illustrations were prepared using Pymol [23].
3. Results and discussion
3.1. X-ray studies show similar interactions between sulfate,
phosphate or N-acetyl groups and the S3 site of ﬁcolin-2
Ficolin-2 binding to DNA [5] and heparin [2] has been observed
previously but not deeply investigated. With a view to better deci-
pher the versatility of the binding properties of ﬁcolin-2, X-ray
structure analyses of its ﬁbrinogen domain were performed with
different sulfated or phosphated compounds using crystal soaking
experiments at different ligand concentrations and incubation
times. We present here in more details the results leading to 2.1
and 2.25 Å diffraction resolution obtained with 300 mM 6SGlcN
and 150 mM SOS, respectively. Statistics of the diffraction data
and model reﬁnement are displayed in Table 1.
As illustrated in Fig. 1 and detailed in Fig 1B and D, these new X-
ray structures show that sulfate groups mainly bind to the pocket
delineated by Arg132, Asp133, Thr136 and Lys221, previously
deﬁned as S3, a binding site initially identiﬁed for acetylated
ligands [9]. Apart from the X-ray structures detailed here, similar
observations were obtained at lower resolution with 150 mM
6SGlcN or 20 mMphosphoglycerate (not shown). This was also true
with 100 mM PCho ([24]; PDB 4NYT) or even with the HEPES buffer
molecule (PDB 2J3U). Fig. 1C illustrates the striking structural bind-
ing similarity of sulfate, phosphate and N-acetyl groups to S3.
3.2. Sulfated and phosphated molecules compete for ﬁcolin-2 binding
The similarity in S3 binding for sulfate, phosphate and N-acetyl
groups (Fig. 1C) suggests their potential competitive binding to ﬁc-
olin-2. Since we have previously shown that ﬁcolin-2 interactsTable 1
Crystallographic data and reﬁnement statistics.
Ligand 6SGlcN SOS
PDB ID 4R9J 4R9T
Space group P3221 P3221
ESRF beamline ID23-eh2 ID23-eh1
Unit cell lengths (Å) a = b = 97.2,
c = 140.0
a = b = 96.1,
c = 141.2
Resolution (Å) 20–2.1 20–2.25
Rsym 9.5 (38.6)a 9.8 (55.3)b
% Completeness 99.8 (100)a 100 (100)b
I/sigma (I) average 22.0 (6.5)a 18.1 (4.8)b
No. of unique reﬂections 45239 (3321)a 36406 (2256)b
Redundancy 11.1 (11.1)a 10.8 (11.1)b
Model statistics
Number of atoms in: protein,
carbohydrate, ligand, water
5281, 53, 85,
234
5206, 28, 31,
61
Resolution (Å) 20–2.1 20–2.25
Rwork 0.172 (0.187)c 0.188 (0.223) d
Rfree 0.203 (0.263)c 0.218 (0.274)d
Root mean square deviation bonds (Å) 0.019 0.016
Root mean square deviation angles () 1.95 1.67
a Statistics for the high-resolution bin (2.15–2.10 Å) are in parentheses.
b Statistics for the high-resolution bin (2.30–2.25 Å) are in parentheses.
c Statistics for the high-resolution bin (2.15–2.10 Å) are in parentheses.
d Statistics for the high-resolution bin (2.31–2.25 Å) are in parentheses.
hFIC-3     FFRSWSSYRAGFG.....HSGRPFTTYDADHDSSNSN
mFIC-A     FFRDWDSYKRGFG.....HNNMSFTTHDQDNDANSMN
mFIC-B     FFRDWTSYKRGFG.....HNNRLFSTKDQDNDGSTSS
FIBCD1     FFRGWDAYRDGFG.....HSGMRFTTKDRDSDHSENN
Fig. 1. The ﬁcolin-2 binding versatility at S3 and its similarity to FIBCD1. (A) Overall
view of the FBG trimer and location of the binding sites in the 6SGlcN study. The N-
terminal extremity (N), the tip region, and locations of the calcium ions and S1, S3
and S4 sites are labeled. One 6SGlcN molecule is bound to S3 on the A (green) and B
(cyan) chains. An additional calcium ion is coordinated to Asp222 near S4 (in A
chain), as previously observed as part of the ß-glucan binding site [9]. An acetate
molecule (Ac) is bound to all the S1 sites, as previously observed in PDB entries
2J3U, 2JOY and 2J1G. (B) Zoom on 6SGlcN binding in S3. The main polar interactions
are displayed. The ligand omit-map is shown in Fig. S2A. (C) Overlay of different S3
ligands, including 6SGlcN (this study), GalNAc (PDB code 2J3F), PCho (PDB code
4NYT), HEPES (PDB code 2J3U). The different natures of the bound chemical groups
are a sulfate (6SGlcN and HEPES), a phosphate (PCho) or N-acetyl (GalNAc). (D)
Superimposition of ﬁcolin-2/SOS in S3 (this study) with FIBCD1 (PDB code 4M7H,
[18]). Only the bound sulfate group can be modeled in the electron density map.
Dashed red lines illustrate the main polar interactions observed in the case of
ﬁcolin-2. The omit-map is shown in Fig. S2B. (E) Partial sequence alignment
including the S3 residues in green; hFIC human ﬁcolin; mFIC: mouse ﬁcolin;
FIBCD1: Fibrinogen C Domain Containing 1 Protein.with immobilized heparin, a highly sulfated molecule, using SPR
spectroscopy [2], this experimental setting was used to show that
SOS competes for ﬁcolin-2 binding to heparin with an IC50 value
estimated to 1.5 mM (Fig. 2A). To conﬁrm that sulfated and
E. Lafﬂy et al. / FEBS Letters 588 (2014) 4694–4700 4697phosphated molecules bind to the same site, we injected ﬁcolin-2
over heparin in the presence of PCho, a recently identiﬁed ligand
shown to bind to the S3 acetyl binding site of ﬁcolin-2 through
its phosphate moiety [24]. As shown in Fig. 2B, the ﬁcolin-2/hepa-
rin interaction was inhibited by PCho (apparent IC50 of 14 mM).
Fig. 2C shows that this interaction could also be inhibited very efﬁ-
ciently by DNA, a phosphate-rich ﬁcolin-2 ligand [5], which yielded
an apparent IC50 value of 0.2 nM (corresponding to a concentra-
tion of 0.25 lg/ml). The polyanionic nature of SOS and DNA seems
to enhance their competition to heparin binding. Moreover, avidity
likely occurs in the case of DNA, contributing to its higher
efﬁciency.
SOS and PCho also acted as competitors for the interaction of
ﬁcolin-2 with immobilized AcBSA, with 30% decreased binding of
ﬁcolin-2 in the presence of 20 mM SOS (not shown) and a 56%
decrease in the presence of 6 mM PCho [24]. The fact that SOS com-
petes less efﬁciently for ﬁcolin-2 binding to AcBSA than to heparin
suggests that acetylated ligands are displaced less easily, which
would be consistent with the known ﬁcolin property to mainly
bind acetylated carbohydrates. Phosphated compounds such as
PCho seem more effective than sulfated ones in these competition
experiments.
Altogether, these experiments are consistent with the structural
view that N-acetylated, sulfated and phosphated ligands bind to0
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Fig. 2. SPR analysis of the competition of SOS (A), PCho (B) and DNA (C) for ﬁcolin-2 bin
20 ll/min in HBS-P in the presence of the indicated concentrations of competitors. The
compared to the value measured in its absence (considered as 100%). Ficolin-2 concentra
and 2.1 lg/ml (5 nM tetramer of trimers) (C). These results are representative of two ind
versus competitor concentration (right panels).the S3 binding site of ﬁcolin-2. They suggest a preference for acet-
ylated ligands, followed by phosphated ones. However the binding
efﬁciency will obviously be inﬂuenced by the presence of repetitive
motifs and/or of multiple charges within physiological ligands such
as DNA and heparin/heparan sulfates.
3.3. A dominant role for Arg132 in the S3 binding property
To further investigate the individual contribution of the amino
acids of the N-acetyl/phosphate/sulfate binding pocket, single
point mutants of ﬁcolin-2 were generated in which the four resi-
dues deﬁning the S3 binding site, Arg132, Asp133, Thr136 and
Lys221, were mutated to Ala. The interaction of the puriﬁed
mutants with heparin was investigated using a solid-phase binding
assay. As illustrated in Fig. 3A, the Arg132A mutation virtually
abolished the ﬁcolin-2/heparin interaction whereas mutation of
Asp133 had a signiﬁcant but less pronounced effect. Mutations of
Thr136 and of Lys221 had no signiﬁcant impact on this interaction.
SPR analysis of the interaction of the ﬁcolin-2 variants with immo-
bilized AcBSA yielded comparable results (Fig. 3B), with a slight
increase in the effect of Asp133 mutation. Altogether, these results
underline the importance of Arg132 in the binding of acetylated
and sulfated groups. As illustrated in Fig. 1B and D, Arg132 pro-
vides indeed three polar interactions, the side-chain contributing0
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Fig. 3. Interaction of ﬁcolin-2 variants with immobilized heparin and acetylated
BSA. (A) Wild-type (wt) or mutated ﬁcolin-2 (0.5 lg) was added to a microtiter
plate coated with 2.5 lg heparin per well. Bound ﬁcolin-2 was detected as
described under Section 2. The signal on control wells coated with 2.5 lg gelatin
was subtracted from the obtained values. Results are means ± S.D. of triplicates and
are representative of two independent experiments. Comparisons between binding
obtained for wt ﬁcolin-2 and each mutant were made using an unpaired Student t
test; two-tailed P values are 0.0044 (R132A), 0.0133 (D133A), 0.1721 (T136A) and
0.391 (K221A). P values <0.05 are considered signiﬁcant. (⁄): P < 0.05; (⁄⁄):
P < 0.005; ns: not signiﬁcant. (B) SPR analysis of the interaction of ﬁcolin-2 variants
with immobilized AcBSA. Sixty ll of each ﬁcolin-2 variant (4.1 lg/ml, 10 nM
tetramer of trimers) were injected over 650 RU of immobilized AcBSA in HBS-P. The
speciﬁc binding signals shown were obtained by subtracting the background signal
over a reference surface with immobilized BSA (950 RU). The results shown are
representative of two independent experiments.
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Fig. 4. Additional sulfate binding at the tip of the FBG domain and comparison with
FIBCD1 and ﬁcolin-1. (A) Sequence alignment of the tip of FBG domain including the
S1 site. Previously identiﬁed S1 residues are highlighted in yellow bold. This site is
non-functional in ﬁcolin-2 because of the Y->F substitution (green) at position 262
[2]. The position of the additional sulfate binding site observed in the SOS study is
displayed under the sequence alignment (+). The charge differences discussed in the
text are highlighted in blue and red. (B) Overview of ﬁcolin-2 FBG domain in the
SOS study. The additional sulfate position and binding site are highlighted at the tip
of the FBG domain. S1, S3 and N-terminus are labeled as in Fig. 1A. (C) Zoom on the
tip area (boxed in B), which is strongly conserved in FIBCD1 (cyan). The blue and red
residues highlighted in A) are strongly conserved in FIBCD1, with identical arginine
(R425) and similar alanine (A429) residues, respectively. The conserved Tyr431
(FIBCD1) and non-conserved Phe262 (ﬁcolin-2) lining S1 are highlighted. (D)
Homologous area in ﬁcolin-1, with the side chain of glutamic acid E269 pointing at
the tip (in red), and a methionine at the position of the arginines in ﬁcolin-2 and
FIBCD1. The conserved Tyr271 lining S1 is also highlighted.
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interface through a salt bridge with Asp111 of the proximal sub-
unit, which explains its conserved elongated conformation [9].
The differential effect of Asp133 mutations in these experiments
suggests that it could be slightly repulsive towards the negatively
charged heparin, which would account for the increased speciﬁcity
for acetylated compounds in S3. The lack of effect of the Lys221
mutation is quite intriguing, but one can imagine that the presence
of Arg132 could compensate for the absence of Lys221. Thr136
locally contributes to stabilizing the ligand in S3 but does not seem
to play a signiﬁcative role in its attraction. In contrast, when
Arg132 is mutated, the buried negative charge of the adjacent
Asp111 is no more compensated and the 132–133 main-chain
conformation of the binding-site could be altered.
Interestingly, binding of a sulfate ion was also recently
described in a homologous site in the FIBCD1 structure which
was crystallized using ammonium sulfate as a precipitating agent
[18]. This sulfate binding-site in FIBCD1 also includes an arginine
(Arg297), homologous to ﬁcolin-2 Arg132, but a glycine and an
alanine at the positions homologous to Asp133 and Thr136, respec-
tively (Fig 1D). Arg297 is similarly engaged in a salt bridge with
Glu311 of the proximal subunit to stabilize the tetrameric inter-
face. The absence of side chain at the position homologous to
Asp133 in ﬁcolin-2 could account for the expected recognition of
highly sulfated compounds by FIBCD1 [18]. The similarity between
ﬁcolin-2 and FIBCD1 sulfate binding in S3 is consistent with themajor contribution of Arg132 observed from mutagenesis studies
on ﬁcolin-2. This arginine side chain and the main-chain peptide
conformation with the following residue deﬁne indeed the major
part of the binding pocket.
3.4. Further details and comparison with homologous proteins suggest
that other residues outside S3 restrict this sulfate/phosphate binding
property
One puzzling question remains however, since the essential
Arg132 in ﬁcolin-2 is strongly conserved in the different ﬁcolins
(Fig. 1E), but ﬁcolins do not all bind sulfated or phosphated ligands.
For example, a very similar but non-functional S3 site is present in
ﬁcolin-1, but ﬁcolin-1 does not bind heparin [2] and its binding to
DNA has never been reported to our knowledge. We performed
similar X-ray structural analyses of the ﬁcolin-1 FBG domain as a
control with high 400 and 500 mM PCho concentrations. We could
not detect signiﬁcant ligand binding at the homologous S3 position
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shown). To explain this discrepancy, we need to take into account
residues outside S3, which would be involved in an initial attrac-
tive or restrictive contact.
Sequence differences occur between ﬁcolin-1 and ﬁcolin-2/FIB-
CD1 at the tip of the recognition domain (Fig. 4A). Interestingly,
an additional sulfate ion was seen in this area in the SOS study
(Fig. 4B and C), H-bonded to the nitrogen main-chain atoms of
Gly260 and Ser261 near the edge of S1 (Phe262). We can propose
that the replacement of Gly260 by a glutamate residue at the tip
of the trimeric FBG domain in the case of human ﬁcolin-1 and
mouse ﬁcolin-A (in red in Fig. 4A and D) could prevent interac-
tions with sulfated and phosphated surfaces. In contrast, a lysine
residue is present at this position in mouse ﬁcolin-B, which has
been described to bind DNA [14], or small residues in the cases
of ﬁcolin-2 (Gly) and FIBCD1 (Ala). Of note, this speciﬁc location
at the tip of the recognition domain enables simultaneous surface
contact by residues of the different subunits of the recognition
domain. These hypotheses remain to be further investigated in
the future, since other charged residues outside S3 might also play
a role in restricting the ﬁcolin selectivity towards polyanionic
ligands.4. Conclusion
The past and present structural studies have revealed the
versatility of ﬁcolin-2 S3, since this site is able to bind sulfate,
phosphate and N-acetyl groups (Fig. 1C). Arg132 plays a major
role in this process, as deduced from point mutation studies
(Fig. 3). Competition experiments appear consistent with this
structural view, since the octasulfated SOS and DNA can compete
efﬁciently with ﬁcolin-2 binding to heparin (Fig. 2). This study
provides one further example on how evolution of this ﬁbrino-
gen-like domain led to an astonishingly wide range of binding
functions [25]. FBG domains can act as trimeric recognition
domains as in ﬁcolins or tetrameric ones in FIBCD1, which thus
implies slight differences in the geometry of their molecular
pattern recognitions. In view of the speciﬁc recognition of the 6-
sulfation molecular pattern by the S3 site (Fig. 1B), further studies
may highlight new functional implications for the interaction of
ﬁcolin-2 with glycosaminoglycans, as well as for FIBCD1. For
example, ﬁcolin-2 was very recently shown to be depleted from
serum by use of heparin-coated cardiopulmonary bypass circuits
[26]. Other functional implications are likely to be discovered in
the future for the recognition by ﬁcolin-2 of phosphated molecu-
lar patterns and/or new ligands at the surface of pathogens, as
illustrated by the recent publication of its binding to phosphocho-
line moieties of pneumococcal teichoic acid [24].
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